Elanco Animal Health Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2024. Elanco Animal Health Inc. is a global leader in animal health, operating as a single segment focused on pet health (dogs and cats) and farm animal health (cattle, poultry, swine). The company divested its aqua business in July 2024 to Merck Animal Health for $1.294 billion. Elanco operates in over 90 countries, with the U.S. representing 46% of total revenue.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $4,439 million | $4,417 million |
| Net Income (Loss) | $338 million | ($1,231 million) |
| Operating Cash Flow | $541 million | $271 million |
| Gross Margin | 55% | 56% |
| Total Debt (Outstanding) | $4.3 billion | $5.8 billion |
| Cash and Equivalents | $468 million | $352 million |
| Goodwill | $4,414 million | $5,094 million |
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability with $338 million in net income, compared to a $1.231 billion loss in 2023. The 2023 loss was significantly impacted by a $1.042 billion goodwill impairment charge, which did not recur in 2024.
- Divestiture Impact: The sale of the aqua business generated a pre-tax gain of $640 million. Proceeds were primarily used to repay $1.6 billion in term loan debt, reducing total indebtedness by approximately $1.5 billion.
- Revenue Stability: Total revenue remained flat year-over-year (+0.5%). Pet Health revenue grew 2% driven by pricing, while Farm Animal revenue declined 1% due to the aqua divestiture and foreign currency headwinds, partially offset by volume growth in cattle and poultry.
- Cost Structure: Cost of sales increased to 45% of revenue (from 44%) due to inflation and product mix changes. Restructuring charges of $44 million were incurred in 2024 to reallocate resources toward pet health.
Guidance, Outlook, and Risks
- Capital Expenditures: Management anticipates 2025 capital expenditures to be between $225 million and $255 million, driven by a $130 million expansion of the biologics manufacturing facility in Elwood, Kansas.
- Product Pipeline: Key launches include Zenrelia (atopic dermatitis in dogs) and Credelio Quattro (broad-spectrum parasite protection). Bovaer (methane-reducing feed additive) began commercial use in the U.S. in Q3 2024.
- Goodwill Sensitivity: Management noted that a further 50 basis-point increase in long-term treasury rates could trigger a quantitative goodwill impairment test, and a 100 basis-point increase would likely result in an impairment charge.
- Legal and Regulatory: The company settled an SEC investigation regarding channel inventory practices for $15 million. It is defending against securities class actions regarding Zenrelia and Credelio Quattro disclosures, as well as antitrust litigation regarding flea and tick products.
- Supply Chain: The company acquired the Speke, U.K. manufacturing facility for $36 million after its former contract manufacturer entered administration, to minimize supply disruption.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the Net Total Leverage Ratio and Fixed Charge Coverage Ratio covenants, given the company's substantial indebtedness.
- Goodwill Valuation: Monitor long-term treasury rates and discount rate assumptions, as these are critical triggers for potential future goodwill impairments.
- Product Adoption: Assess the commercial uptake of Zenrelia (which carries a boxed warning) and Credelio Quattro to validate growth assumptions in the pet health segment.
- Legal Exposure: Track the status of pending securities class actions and antitrust litigation, which could result in significant damages or reputational harm.
- Antibiotic Regulations: Monitor regulatory changes regarding shared-class antibiotics in farm animals, which could impact revenue from products like Baytril and Pulmotil.